Wall Street Used Claude to Design a Drug. Now It's a Trade.
Sell-side researchers used Anthropic's Claude to design a drug, and the experiment has already produced a new investment thesis for Wall Street.
Topic
Pharma
Topic
Pharma
Novo Nordisk Strikes Second Licensing Deal After Rough Capital Markets Day
Novo Nordisk on Tuesday struck its second licensing deal since investors gave its long-term strategy a poor reception at its capi…
Novo's Wegovy Pill Delivers Further Weight Loss for Injection Switchers
Novo says patients switching from Wegovy or Zepbound injections to its new pill lost another 8.8 pounds on average in three month…
Servier Hires Senior Investment Director for Corporate VC Arm
Servier has recruited a new senior investment director for its corporate venture capital arm, Global Venturing reports, signaling…
Kardigan Turned Deal Leftovers Into a $400M IPO
Kardigan raised $400 million in an IPO built on programs discarded from a prior deal, BioPharma Dive reports — a spin-out play pu…
Incyte Gains 22.5% in Three Months, Beating Biotech Peers
Incyte (INCY) is up 22.5% in three months, beating XBI's 11%, after Q2 sales jumped 40.5% to $1.5 billion and management raised F…
Ex-Gilead Executive's Novel-Drug Startup Targets $1 Billion IPO Valuation
A startup founded by a onetime Gilead Sciences executive is pursuing an initial public offering at a $1 billion valuation, The Bu…